Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OGT | O15294 | 6/20 | 0.63 |
| ▸ | PKM | P14618 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 4/20 | 0.51 |
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | THRB | P10828 | 2/20 | 0.47 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 3/20 | 0.43 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4544684 | 0.87 | OGT (0.59) | OGTPKMPOLBMAPTTHRB | |
| SCHEMBL4547032 | 0.86 | PKM (0.58) | OGTPKMPOLBMAPTTHRB | |
| SCHEMBL4544736 | 0.85 | OGT (0.60) | OGTPKMPOLBMAPTTHRB | |
| SCHEMBL17405139 | 0.85 | OGT (0.53) | OGTPKMPOLBMAPTTHRB | |
| SCHEMBL17405140 | 0.85 | OGT (0.62) | OGTPKMPOLBMAPTTHRB | |
| SCHEMBL4544657 | 0.85 | OGT (0.62) | OGTPKMPOLBMAPTTHRB | |
| SCHEMBL4544645 | 0.84 | OGT (0.55) | OGTPKMPOLBMAPTTHRB | |
| SCHEMBL23815544 | 0.82 | OGT (0.52) | OGTPKMPOLBMAPTTHRB | |
| SCHEMBL4544695 | 0.81 | OGT (0.63) | OGTPKMPOLBMAPTTHRB | |
| SCHEMBL17406933 | 0.81 | OGT (0.74) | OGTPKMPOLBMAPTTHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170166558-A1 | O-GLCNAC TRANSFERASE (OGT) INHIBITORS AND USES THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2017-06-15 | — | — | US | disclosed |
| US-20170166558-A1 | O-GLCNAC TRANSFERASE (OGT) INHIBITORS AND USES THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2017-06-15 | — | — | US | disclosed |
| WO-2016004180-A1 | O-GLCNAC TRANSFERASE (OGT) INHIBITORS AND USES THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2016-01-07 | — | — | WO | disclosed |
| US-8957075-B2 | O-GlcNAc transferase inhibitors and uses thereof | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2015-02-17 | — | — | US | disclosed |
| US-8957075-B2 | O-GlcNAc transferase inhibitors and uses thereof | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2015-02-17 | — | — | US | disclosed |
| US-20120108605-A1 | O-GLCNAC TRANSFERASE INHIBITORS AND USES THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2012-05-03 | — | — | US | disclosed |
| US-20120108605-A1 | O-GLCNAC TRANSFERASE INHIBITORS AND USES THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2012-05-03 | — | — | US | disclosed |
| WO-2010141074-A2 | O-GLCNAC TRANSFERASE INHIBITORS AND USES THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2010-12-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170166558-A1 | O-GLCNAC TRANSFERASE (OGT) INHIBITORS AND USES THEREOF | OGA, OGT, CSGALNACT1 | OGT 2/4885PKM 3290/4885POLB 1553/4885 |
| US-20120108605-A1 | O-GLCNAC TRANSFERASE INHIBITORS AND USES THEREOF | OGA, OGT, UGGT1 | OGT 2/4885PKM 4502/4885POLB 3030/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.